Key statistics
As of last trade, BridgeBio Pharma Inc (2CL:STU) traded at 22.61, 10.35% above the 52 week low of 20.49 set on Jun 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.75 |
---|---|
High | 22.77 |
Low | 22.61 |
Bid | 22.53 |
Offer | 22.78 |
Previous close | 23.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 188.03m |
Free float | 151.35m |
P/E (TTM) | -- |
Market cap | 4.67bn USD |
EPS (TTM) | -2.64 USD |
Data delayed at least 15 minutes, as of Oct 07 2024.
More ▼
Announcements
- BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
- BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
- BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
- BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
- BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
- BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
- BridgeBio Pharma to Participate in September Investor Events
More ▼